FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2526-2527 June 10, 2004 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McCormack, M. P. PubMed Citation

To the Editor: McCormack and Rabbitts (Feb. 26 issue)¹ discuss the role of activation of the T-cell oncogene LMO2 in inducing clonal T-cell proliferation in two patients after gene therapy for X-linked severe combined immunodeficiency (SCID), a condition caused by mutation of the c cytokine-receptor subunit gene. The authors point to a role of c as a cofactor of clonal proliferation. However, there are no data to suggest that, as proposed, the expression of a CD25–c interleukin-2–receptor complex by T-cell precursors will make these cells hypersensitive to interleukin-2, since signal transduction without the R subunit of interleukin-2 is highly . . . [Full Text of this Article]

This article has been cited by other articles:

• Cotrim, A. P., Baum, B. J. (2008). Gene Therapy: Some History, Applications, Problems, and Prospects. Toxicol Pathol 36: 97-103 [Abstract] [Full Text]  
• Lodde, B M, Baum, B J, Tak, P P, Illei, G (2006). Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment. Ann Rheum Dis 65: 1406-1413 [Abstract] [Full Text]  
• Shou, Y., Ma, Z., Lu, T., Sorrentino, B. P. (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. USA 103: 11730-11735 [Abstract] [Full Text]  
• De Palma, M., Montini, E., de Sio, F. R. S., Benedicenti, F., Gentile, A., Medico, E., Naldini, L. (2005). Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105: 2307-2315 [Abstract] [Full Text]